Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Seasonal Influenza

Seasonal Influenza

Part of Orthomyxoviridae Infections

5 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Seasonal Influenza

14 trials tracked for Seasonal Influenza: 6 in phase 3 or 4 and 1 with published results. The most-cited published study has 84 citations.

14Trials tracked
6Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 1 Phase 3 5 Phase 2 7 Phase 1 1
  1. Phase 3 Study of mRNA-1010 Seasonal Influenza Vaccine in Adults Completed · 84 cited
  2. Phase 4 Safety of a Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs in Adults and Elderly With and Without Underlying Medical Conditions, and Immunogenicity in a Subset of Subjects With Underlying Medical Conditions Completed
  3. Phase 3 A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults Completed
  4. Phase 3 A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older Completed
  5. Phase 3 Safety and Immunogenicity of Trivalent Subunit Inactivated Flu Vaccine Administered to Healthy Children and Adolescents 3 to 17 Years of Age Completed
  6. Phase 3 Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza Completed
Show 8 more trials
  1. Phase 2 A Study of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults Completed
  2. Phase 2 Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects Completed
  3. Phase 2 A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults Completed
  4. Phase 2 A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults Completed
  5. Phase 2 Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted With MF59C.1, Seasonal Influenza Vaccine, Formulation 2009-2010 Completed
  6. Phase 2 Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2010-2011 Completed
  7. Phase 2 Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2011-2012 Completed
  8. Phase 1 First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV in Healthy Adults Completed

Showing the 14 most-cited and recently-updated of 14 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Seasonal Influenza: what the trials found

Several established trials evaluated the immunogenicity and efficacy of mRNA-1010, a seasonal influenza vaccine. In a phase 3 trial (N=8411), mRNA-1010 induced seroconversion rates ranging from 34.9% to 64.4% across strains, with 92.0% to 96.7% of participants achieving HAI titers ≥1:40 2. Another large phase 3 trial (N=22502) reported seroconversion rates of 29.4% to 52.0% and HAI titers ≥1:40 in 85.5% to 94.8% of participants 3. A third phase 3 trial (N=6102) showed seroconversion rates of 32.4% to 80.1% and HAI titers ≥1:40 in 80.7% to 97.6% 4. However, in the efficacy analysis, mRNA-1010 did not significantly reduce the first episode of RT-PCR-confirmed influenza-like illness (ILI) caused by any seasonal influenza strain (142 vs 140 events; p=0.1715) 3. In a phase 1/2 trial (N=885), seroconversion rates with mRNA-1010 ranged from 4.9% to 90.2% depending on dose and strain 9.

A cell-derived influenza vaccine (cTIV) was compared to traditional TIV in a phase 4 trial (N=1398). Among subjects with underlying medical conditions, the percentages achieving HAI titers ≥40 after one vaccination ranged from 40% to 98% for cTIV and TIV, with seroconversion rates of 56% to 72% 1. A phase 3 trial (N=3116) of TIV reported seroconversion rates of 78% to 95% and HAI titers ≥40 in 48% to 97% of subjects 6. For the antiviral peramivir, a phase 3 trial (N=234) showed a change from baseline in influenza virus titer at 48 hours of -1.66 vs -1.47 5.

Recent results — preliminary, needs further review

  • A phase 2 trial (N=698) of mRNA-1011.1 reported geometric mean fold rises (GMFR) of anti-HA antibodies at day 29 ranging from 2.7 to 3.7 across strains, with seroconversion rates of 35.9% to 49.4% 7.
  • Another phase 2 trial (N=572) of mRNA-1030 showed GMFRs of 5.29 to 9.93 and seroconversion rates of 56.7% to 75.4% 8.
  • Several small phase 2 trials (N=63-84) evaluated MF59-adjuvanted subunit influenza vaccines. One trial (N=84) reported seroconversion rates of 53% to 100% and HI titers >1:40 in 57% to 100% 10. Three other trials (N=63-64) using FLUAD showed seroconversion or significant increase in SRH area ranging from 26% to 69% 11, 43% to 46% 12, and 27% to 61% 13.
  • A phase 1 trial (N=63) of an Adjuplex-adjuvanted vaccine (VRC-GENADJ0110-AP-NV) reported local and systemic reactogenicity within 7 days, with 0-12 participants reporting local symptoms and 1-13 reporting systemic symptoms across dose groups 14.

For the clinician treating this condition

  • mRNA-1010 induces robust antibody responses (seroconversion and HAI titers ≥1:40) across multiple phase 3 trials, but did not demonstrate significant efficacy against RT-PCR-confirmed ILI in one large trial 234.
  • Cell-derived and traditional TIV vaccines show comparable immunogenicity in subjects with underlying medical conditions and in general populations 16.
  • Peramivir reduces influenza virus titers at 48 hours compared to baseline 5.

AI synthesis of 14 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
mRNA-1010 shows superior efficacy against influenza in older adults
Drug Pipeline RCT
mRNA-1010 shows superior efficacy against influenza in older adults New flu shot cuts illness by 27 percent in adults over 50
A phase 3 trial found mRNA-1010 vaccine had 26.6% relative efficacy versus standard comparator in adults 50+.
A new mRNA flu vaccine reduced confirmed flu illness by 27 percent compared with the standard shot in adults 50 and older.
May 7, 2026
Coadministration of RSV mRNA vaccine and high-dose flu vaccine noninferior for flu but not for RSV in older adults
Drug Pipeline RCT
Coadministration of RSV mRNA vaccine and high-dose flu vaccine noninferior for flu but not for RSV in older adults New data shows RSV and flu shots work well together
This phase 3 randomized controlled trial in 1900 adults aged 65 and older compared coadministration of mRNA-1345 and quadrivalent influenza …
Older adults can now get their RSV and flu vaccines during one visit without safety risks or extra trips to the clinic for care.
Apr 29, 2026
ACIP Issues Recommendations for Seasonal Influenza Prevention and Control with Vaccines
Allergy & Immunology
ACIP Issues Recommendations for Seasonal Influenza Prevention and Control with Vaccines What's the latest advice on flu shots this season?
The Advisory Committee on Immunization Practices (ACIP) has published recommendations for the prevention and control of seasonal influenza u…
U.S. health officials released updated flu shot advice for the 2023-24 season, emphasizing vaccination as the core way to prevent and contro…
CDC Apr 4, 2026
ACIP Issues Recommendations for Seasonal Influenza Vaccine Use in 2022-23
Allergy & Immunology
ACIP Issues Recommendations for Seasonal Influenza Vaccine Use in 2022-23 What flu shot should you get this year? Here are the official recommendations
The Advisory Committee on Immunization Practices (ACIP) has published its annual recommendations for seasonal influenza vaccine use in the U…
The 2022-23 flu season has official vaccine recommendations from experts to help you get the best protection against circulating strains.
CDC Apr 4, 2026
CDC Issues Recommendations for Seasonal Influenza Prevention and Control with Vaccines
Allergy & Immunology
CDC Issues Recommendations for Seasonal Influenza Prevention and Control with Vaccines Health officials release updated recommendations for seasonal flu vaccines
The CDC has published recommendations and reports for the prevention and control of seasonal influenza with vaccines in the United States.
CDC releases updated flu vaccine guidance for the upcoming season, advising doctors and the public on who should get vaccinated and when.
CDC Apr 3, 2026

Research across Orthomyxoviridae Infections

Related studies from across the Orthomyxoviridae Infections family.

Systems-oriented One Health approach addresses structural and social barriers in family poultry disease control
Psychiatry Sys. Review
Systems-oriented One Health approach addresses structural and social barriers in family poultry disease control New strategies help family poultry farmers control bird flu risks
This rapid review synthesizes 110 peer-reviewed publications and 27 policy documents regarding HPAI and LPAI control in family poultry syste…
Small-scale poultry farmers face unique hurdles in stopping bird flu. New research highlights how local knowledge and fair policies can impr…
Frontiers Oct 20, 2026
Respiratory viruses linked to pediatric acute necrotizing encephalopathy in meta-analysis
Neurology Meta-analysis
Respiratory viruses linked to pediatric acute necrotizing encephalopathy in meta-analysis Understanding the link between respiratory viruses and brain inflammation in children
This meta-analysis examines the association between respiratory viral infections, specifically influenza viruses and SARS-CoV-2, and acute n…
New data looks at how common viruses like flu and COVID-19 can lead to serious brain swelling in young patients.
Frontiers Oct 16, 2026
Early LAIV administration leads to 2.5-times increased odds of pneumococcal density at 14 days
Pediatrics RCT
Early LAIV administration leads to 2.5-times increased odds of pneumococcal density at 14 days Flu vaccine may increase bacteria levels in children and families
This randomized controlled trial of 405 families in the UK found that early live attenuated influenza vaccine (LAIV) significantly increased…
A new study shows that a specific flu vaccine can cause a temporary spike in bacteria that may spread to family members.
Oct 4, 2026
Influenza vaccination rate among Chinese health care workers pooled at 27%
Primary Care & Family Medicine Meta-analysis
Influenza vaccination rate among Chinese health care workers pooled at 27% Factors that help healthcare workers get flu shots in China
This meta-analysis of observational studies estimates the influenza vaccination rate among health care workers in China at 27% (95% CI: 21-3…
New data identifies specific factors like age, income, and workplace rules that help healthcare workers decide to get their flu shots.
Frontiers Sep 21, 2026
Bangga extracts show antibacterial, anti-inflammatory, antiviral, and antitumor activity in preclinical synthesis
Drug Pipeline Sys. Review
Bangga extracts show antibacterial, anti-inflammatory, antiviral, and antitumor activity in preclinical synthesis Extracts of Aconitum tanguticum Show Potential for Several Conditions
This systematic review synthesizes preclinical evidence on Aconitum tanguticum (Bangga), reporting antibacterial, anti-inflammatory, antivir…
Research into Aconitum tanguticum extracts shows potential antibacterial, antiviral, and anti-inflammatory properties for various inflammato…
Frontiers Sep 13, 2026
Recombinant influenza vaccine yields higher A(H1N1) and A(H3N2) titers in adults with severe obesity
Diabetes & Endocrinology RCT
Recombinant influenza vaccine yields higher A(H1N1) and A(H3N2) titers in adults with severe obesity Recombinant flu vaccine shows stronger immune response in people with obesity
This randomized clinical trial of 206 adults with severe obesity (BMI ≥35 kg/m2) found that a recombinant influenza vaccine (RIV) produced h…
A new trial shows a recombinant flu vaccine creates a stronger immune response than standard egg-based vaccines for people with severe obesi…
Sep 9, 2026
Opt-out nudge reduces number of unvaccinated medical residents by 81% for influenza
Primary Care & Family Medicine RCT
Opt-out nudge reduces number of unvaccinated medical residents by 81% for influenza Opt-out Nudges Increase Influenza Vaccination Rates Among Medical Residents
This randomized controlled trial of 260 medical residents in France found that an opt-out nudge significantly increased vaccination rates. T…
A simple opt-out nudge significantly increased flu vaccination rates among medical residents while maintaining their sense of personal choic…
Aug 30, 2026
Seasonal influenza vaccine effectiveness increased against A(H3N2) and B strains in post-pandemic period
Pediatrics Meta-analysis
Seasonal influenza vaccine effectiveness increased against A(H3N2) and B strains in post-pandemic period Flu vaccine effectiveness shows changes after the COVID-19 pandemic
This meta-analysis of 85 publications analyzed seasonal influenza vaccine effectiveness (VE) comparing pre-pandemic (2010/11-2019/20) and po…
New data reveals that flu vaccines have shown higher effectiveness against certain strains since the COVID-19 pandemic began.
Aug 13, 2026
Pregnancy raises influenza susceptibility and severity, with potential fetal neurological effects
Urology Sys. Review
Pregnancy raises influenza susceptibility and severity, with potential fetal neurological effects Pregnancy makes women more likely to get severe flu infections
This systematic review synthesizes evidence on influenza in pregnancy, finding increased susceptibility and severity due to physiological im…
Pregnant people face a higher risk of serious complications from the flu because of natural changes in their immune systems during pregnancy…
Frontiers Aug 5, 2026
Toll-like receptor signaling governs inflammatory phenotypes and progression in infectious myocarditis
Cardiology Sys. Review
Toll-like receptor signaling governs inflammatory phenotypes and progression in infectious myocarditis Toll-like receptors shape severity of infectious myocarditis
This systematic review examines the role of toll-like receptors (TLRs) in infectious myocarditis associated with COVID-19, influenza, and se…
A systematic review finds that pathogen-specific TLR signaling determines inflammation and outcomes in infectious myocarditis, with COVID-19…
Frontiers Jul 15, 2026
Respiratory viral coinfections reshape immune signaling and granuloma stability in Mycobacterium tuberculosis infections
Nephrology Sys. Review
Respiratory viral coinfections reshape immune signaling and granuloma stability in Mycobacterium tuberculosis infections Viral Infections May Change How the Body Fights Tuberculosis
This narrative review synthesizes how respiratory viruses, including SARS-CoV-2 and influenza, impact host immune signaling and granuloma eq…
Research shows that common respiratory viruses like flu or COVID-19 can change how the immune system responds to tuberculosis infections.
Frontiers Jul 4, 2026
Many healthcare students lack knowledge that antibiotics do not speed recovery from colds and flu
Infectious Disease Meta-analysis
Many healthcare students lack knowledge that antibiotics do not speed recovery from colds and flu Healthcare students often lack clear knowledge on antibiotics and viruses
This meta-analysis of 131 studies from 43 countries found that while 88.7% of healthcare students correctly knew antibiotics treat bacterial…
Many healthcare students are unsure if antibiotics can treat common colds or flu, which may lead to improper use of these important medicine…
Jul 3, 2026

Questions about Seasonal Influenza

Can I get the RSV and seasonal influenza vaccines at the same time?

Yes, you can get the RSV and seasonal influenza vaccines at the same time. Research shows this is safe and does not reduce the effectiveness of the flu shot.

Full answer →